{
  "docId": "019de072-c7f4-719d-b60b-87ffd56a191c",
  "docSlug": "e58df8a62ccd3bd6cd3ca8f1cf8222ea",
  "documentTitle": "MindMed | Results Presentation Deck | 40 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 40,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Slide contains two distinct charts labeled A and B, referencing specific research papers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c7f4-719d-b60b-87ffd56a191c/20",
  "deckHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c",
  "deckJsonHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c.json",
  "deckAnchorHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.52,
        "w": 0.38,
        "x": 0.138,
        "y": 0.35
      },
      "kind": "chart",
      "text": "A: Percent of baseline dopamine release for Ibogaine and 18-MC variants",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5c63161-d6a5-47da-9baa-6f6793093e49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.38,
        "x": 0.57,
        "y": 0.35
      },
      "kind": "chart",
      "text": "B: Locomotor activity vs Morphine dosage for VEH and 18-MC",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b189a3a1-664b-474e-ad7e-7f12dbaa02d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.82,
        "x": 0.138,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "18-MC decreases (A) extracellular dopamine release in the accumbens and (B) dopamine sensitization following chronic morphine exposure",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da6ecfab-0407-4c2c-8daf-3d9f22f95b62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.1,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Glick & Maisonneuve, 2000; Szumlinski et al., 2000",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a365ee0d-1ccd-4556-b43c-8081b8886a86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.138,
        "y": 0.02
      },
      "kind": "title",
      "text": "Reduces Dopamine Release",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3682acbf-f04d-4c89-9ca1-b26bbcee7b99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "57bb3b38-2ce1-46d4-bf13-5091298ed329",
      "evidence": "chart/bar-vertical: A: Percent of baseline dopamine release for Ibogaine and 18-MC variants",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 17,
      "beatId": "8b3edd16-18bb-4450-a68c-0765c795a4f7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 17-33 present Zolunicant as a potential solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 17,
      "name": "Trojan Horse",
      "slug": "29-trojan-horse",
      "bestFor": "Upselling, expanding scope, introducing new initiatives",
      "matchId": "35ee55af-a6fd-4477-b4a6-df3a1b7717d1",
      "evidence": "Slides 17-25 present Zolunicant as a novel solution.",
      "position": 1,
      "objective": "How can Zolunicant be a Trojan horse for addressing opioid use disorder?",
      "structure": "The Obvious Win (What They Want) -> The Hidden Opportunity -> The Bigger Vision",
      "confidence": 0.6,
      "description": "Lead with something they already want, then reveal the bigger opportunity inside"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}